Actonel can interact with several other medications. It can also interact with certain supplements as well as certain foods. Different interactions can cause different effects. For instance, some interactions can interfere with how well a drug works.
Other interactions can increase side effects or make them more severe. Using certain medications with Actonel could decrease how well Actonel is able to work in your body. Below, we describe a group of medications that may affect Actonel in this way. Before taking Actonel, talk with your doctor and pharmacist.
Tell them about all prescription, over-the-counter, and other drugs you take. Also tell them about any vitamins, herbs, and supplements you use.
Sharing this information can help you avoid potential interactions. Taking Actonel with antacids may cause Actonel to not work as well in your body. Antacids are used to treat heartburn. And keep in mind that Actonel should be taken in the morning. But be sure to talk with your doctor about when you should take doses of Actonel and antacids.
Using certain supplements with Actonel could decrease how well Actonel is able to work in your body. Below, we describe supplements that may affect Actonel in this way. They may do so if:. Taking these supplements too close to the time when you take Actonel may cause Actonel not to work as well as it should.
This is because taking Actonel with liquids other than water or eating too soon after taking Actonel may prevent your body from properly absorbing Actonel. Actonel is known to interact with certain agents used to diagnose bone conditions. Called bone-imaging agents, these substances are used for certain tests to help doctors look for problems in your bones.
Because Actonel affects how your bones are made, it can interfere with these types of tests. Be sure to tell your doctor about all the medications you take, including Actonel. As with all medications, the cost of Actonel can vary. To find current prices for Actonel tablets in your area, check out GoodRx.
The cost you find on GoodRx. If you need financial support to pay for Actonel, help is available. NeedyMeds lists programs that may provide assistance to lower the cost of Actonel. Actonel is available in a generic form called risedronate. And generics tend to cost less than brand-name drugs. To find out how the cost of risedronate compares to the cost of Actonel, visit GoodRx.
They may have a preference for one version or the other. Actonel must be taken on an empty stomach. This medication should be taken with a full glass of water. Then you should wait at least 30 minutes before ingesting any other liquids or foods. Instead, Actonel tablets should be swallowed whole with a glass of water. And with this condition, bone fractures can occur more easily than usual. Actonel belongs to a group of drugs called bisphosphonates.
And they help to increase the thickness of your bone tissue. Specifically, Actonel works by decreasing the activity of cells in your body called osteoclasts. These cells break down bone cells as your bone tissue makes new bone cells. This helps to improve the strength and thickness of your bone tissue.
Actonel starts to work in your system right away. In fact, Actonel helps to reduce breakdown of your bone tissue within 14 days of use. Animal studies have shown some risk to developing pregnancies when Actonel was given to pregnant females. If you become pregnant or think you may be pregnant while taking Actonel, talk with your doctor right away.
The manufacturer of Actonel recommends that you stop taking Actonel once a pregnancy is confirmed. This drug comes with several precautions. Before taking Actonel, talk with your doctor about your health history.
Actonel may not be right for you if you have certain medical conditions or other factors affecting your health. Using more than the recommended dosage of Actonel can lead to serious side effects.
Do not use more Actonel than your doctor recommends. You can also call the American Association of Poison Control Centers at or use their online tool. But if your symptoms are severe, call or your local emergency number, or go to the nearest emergency room right away. When you get Actonel from the pharmacy, the pharmacist will add an expiration date to the label on the bottle. This date is typically 1 year from the date they dispensed the medication.
The expiration date helps guarantee that the medication is effective during this time. If you have unused medication that has gone past the expiration date, talk to your pharmacist about whether you might still be able to use it.
How long a medication remains good can depend on many factors, including how and where you store the medication.
They should be kept in a tightly sealed container away from light. Avoid storing this medication in areas where it could get damp or wet, such as bathrooms. This helps prevent others, including children and pets, from taking the drug by accident. It also helps keep the drug from harming the environment. This article provides several useful tips on medication disposal. You can also ask your pharmacist for information on how to dispose of your medication. Actonel comes as tablets that are administered by mouth.
Dosage varies by the condition being treated. Actonel contains the bisphosphonate risedronate. Risedronate acts by slowing bone cell turnover and reducing resorption to slow loss of bone and help increase bone thickness. Absolute bioavailability of Actonel is up to 0. Steady-state concentration is reached within 57 days of daily dosing. The elimination half-life of Actonel is approximately 23 days. Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date.
However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or other healthcare professional before taking any medication.
The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Bone density decreases with time, and some people have a risk of developing weak or brittle bones. Learn how to increase or maintain bone density here.
People may feel aches or pains in their bones for a variety of reasons. Many people worry when they experience bone pain because it can be a sign of….
A bone fracture is another term for a broken bone. Depending on the location, type, and severity of the fracture, a doctor may recommend different…. Vitamin D can improve bone, muscle, and immune system health. Foods with a high vitamin D content include oily fish, some mushrooms, and egg yolks…. Tymlos abaloparatide is a prescription injection to treat osteoporosis after menopause.
Learn about side effects, dosage, alternatives, and more. Actonel risedronate. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor.
Do not stop taking this medication without consulting your doctor. Do not give this medication to anyone else, even if they have the same symptoms as you do. It can be harmful for people to take this medication if their doctor has not prescribed it.
Each delayed-release, oval-shaped, yellow tablet with "EC 35" engraved on one side contains risedronate 35 mg. Nonmedicinal ingredients: edetate disodium, ferric oxide yellow, magnesium stearate, methacrylic acid copolymer dispersion, silicified microcrystalline cellulose, polysorbate 80, simethicone, sodium starch glycolate, stearic acid, talc, and triethyl citrate.
The usual dose of risedronate delayed-release is 35 mg taken once a week in the morning with breakfast. Do not take this medication before breakfast or on an empty stomach. Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
Swallow the tablet whole do not chew, crush, or cut it with at least mL 4 ounces of plain water. Do not lie down for at least 30 minutes after taking the tablet. Calcium supplements and antacids can interfere with how well this medication works and should be taken at a different time of day.
It is important to take this medication exactly as prescribed by your doctor. If you miss a dose, take the missed dose the following day and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice. Store this medication at room temperature, protect it from light and moisture, and keep it out of the reach of children.
Do not dispose of medications in wastewater e. Ask your pharmacist how to dispose of medications that are no longer needed or have expired. Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes this medication. If you are concerned about side effects, discuss the risks and benefits of this medication with your doctor. Many of these side effects can be managed, and some may go away on their own over time. Contact your doctor if you experience these side effects and they are severe or bothersome.
Your pharmacist may be able to advise you on managing side effects. Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not seek medical attention. Stop taking the medication and seek immediate medical attention if any of the following occur:.
Some people may experience side effects other than those listed. Small decreases in serum calcium and the expected reciprocal increases in serum iPTH 1—84 were seen within the first few weeks of treatment, as expected upon initiation of antiresorptive therapy. These changes were transient and were not symptomatic or clinically meaningful.
No clinically important differences were seen across groups for any laboratory parameter measured, including measures of hepatic and renal function. Other laboratory safety parameters, including fecal occult blood tests, coagulation parameters, and electrocardiograms, revealed no adverse safety signals.
Risedronate, as an IR tablet, has proven vertebral and nonvertebral antifracture efficacy. Due to poor bioavailability in the presence of food with all bisphosphonates, it is important that these medications be taken before the first food or drink of the day for optimal efficacy. With risedronate, patients must wait at least 30 min after dosing before eating or drinking anything other than water.
This study has shown that the novel risedronate 35 mg DR tablet, when taken once weekly either before or after breakfast, produces clinical effects similar to those seen with the risedronate 5 mg IR tablet taken daily as prescribed. Specifically, the mean percent changes in lumbar spine BMD at 52 weeks in the DR weekly groups were non-inferior to the mean percent change in the IR daily group. Changes in secondary efficacy parameters, including BMD at the hip, bone turnover markers and new morphometric vertebral fractures were generally similar in both DR weekly groups compared to the IR daily group.
Statistically significant increases in femoral neck BMD, and decreases in bone turnover markers, were seen at some time points in the DR weekly groups compared to the IR daily group.
The reason for the somewhat increased responses to the DR regimen is unclear but is probably not explained by the difference in daily versus weekly dosing since the BMD and marker responses to daily and weekly risedronate IR did not differ [ 14 ]. Even a modestly better bioavailability of the DR formulation compared to IR during the year of therapy could account for the difference. Alternatively, perhaps compliance with dosing instructions was better with the weekly DR regimen compared to the daily IR regimen, even in the context of clinical trial where compliance with therapy is generally better than in daily clinical practice.
The risedronate DR weekly regimen was generally well tolerated by postmenopausal women, with a safety profile similar to that seen with the risedronate daily regimen. Although upper abdominal pain and diarrhea were more frequent in the DR weekly groups, few subjects withdrew due to the events.
Most events were mild or moderate in severity, suggesting these symptoms with the 35 mg DR weekly regimen will have a minimal impact on adherence to treatment in clinical use. The vertebral and nonvertebral antifracture efficacy of risedronate has been established in multiple large studies that had fracture as the primary Endpoint [ 12 , 15 , 16 ].
BMD change is an appropriate surrogate Endpoint when evaluating a new dosing regimen for a bisphosphonate for which a fracture benefit has already been established. Similar non-inferiority trials have been conducted previously to evaluate new dosing regimens of oral and intravenous bisphosphonates [ 11 , 17 , 18 ], and this approach has been accepted by both the United States Food and Drug Administration and the European Medicines Agency [ 14 ] for approval of new regimens of established agents.
The Year 1 BMD results observed in this study are consistent with what has been observed in the pivotal antifracture studies and other previous studies of risedronate IR weekly and monthly dosing regimens [ 11 , 13 , 19 ]. These results were obtained with specific dosing regimens. The data presented here pertain only to dosing with risedronate DR at least 30 min before or immediately after breakfast and may not reflect the responses to taking the new formulation at other times.
It is also important to note that calcium supplements were taken at a time of day different than the risedronate doses and that the effect of taking calcium supplements around the time of breakfast on the day the DR formulation was taken is not known. All subjects were required to remain upright after taking the study tablets since they might have been taking risedronate IR.
As a result, the requirement to remain upright after dosing persists with risedronate DR. In theory, having the DR formulation disintegrate in the small intestine rather than the esophagus or stomach should decrease the potential for reflux of the drug into the esophagus and esophageal irritation. The study was not designed to evaluate that outcome. In summary, the risedronate 35 mg DR weekly dosing regimen, taken before or following breakfast, was similar in efficacy and tolerability to risedronate 5 mg IR daily dosing in postmenopausal women with osteoporosis.
By minimizing the impact of concomitantly ingested food on the bioavailability of risedronate, the 35 mg DR tablet, taken in the morning once a week without regard to food or drink, could make it easier for patients to accept and comply with therapy, thus improving the effectiveness of risedronate in clinical practice.
Risedronate 35 mg as a delayed-release tablet taken once weekly before or after breakfast provides a simplified dosing regimen for the patient while ensuring the full efficacy of risedronate.
Nelson Warner Chilcott Pharmaceuticals Inc. The authors are responsible for the content, editorial decisions, and opinions expressed in the article. The authors would also like to thank the other principal investigators who participated in this study. The principal investigators at each study site were: Argentina—C. Magaril, Buenos Aires; Z. Man, Buenos Aires; C. Mautalen, Buenos Aires; J. Zanchetta, Buenos Aires. Kaufman, Gent. Bensen, Hamilton, Ontario; J. Faraawi, Kitchener, Ontario; W.
Olszynski, Saskatoon, Saskatchewan; L. Maasalu, Tartu; K. Valter, Tallinn. Benhamou, Orleans; R. Chapurlat, Lyon; P. Fardellone, Amiens; G. Balogh, Debrecen; K. Lakatos, Budapest; L. Nagy, Eger. Badurski, Bialystok; J. Marcinowska-Suchowierska, Warszawa; A. United States—M. Bolognese, Bethesda, MD; D. Kroll, Seattle, WA; M. Miller, Lakewood, CO; J. Moffett, Jr. Nattrass, Seattle, WA; C. Recknor, Gainesville, GA; K. Saag, Birmingham, AL; J.
Salazar, Melbourne, FL; R. Samaan, Brockton, MA; S. Trupin, Champaign, IL; M. Warren, Greenville, NC; R. Weinstein, Walnut Creek, CA. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author s and source are credited.
Trial Registration: clinicaltrials. This study was funded and supported by Warner Chilcott Pharmaceuticals Inc. National Center for Biotechnology Information , U. Osteoporosis International. Osteoporos Int. Published online Sep McClung , 1 P. Miller , 2 J. Brown , 3 J. Zanchetta , 4 M.
0コメント